Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF

Abstract Introduction To evaluate long-term outcomes of anti-VEGF therapy for neovascular age-related macular degeneration (nAMD) in the Netherlands (NL), where bevacizumab is the mandated first-line drug, compared to high-income countries using ranibizumab or aflibercept as initial treatments. Meth...

Full description

Saved in:
Bibliographic Details
Main Authors: H. Mhmud, J. P. Vermeulen, O. A. M. Tigchelaar-Besling, F. D. Verbraak, D. Barthelmes, M. Gillies, T. L. Ponsioen, Caroline C. W. Klaver
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-06-01
Series:Ophthalmology and Therapy
Subjects:
Age-related macular degeneration
Neovascular AMD
Bevacizumab
AMD management
Online Access:https://doi.org/10.1007/s40123-025-01178-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items